An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

The Biden administration has proposed expanding coverage for weight loss drugs. The proposed rule, which requires a lengthy ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

The move comes more than 30 years since the Food and Drug Administration prohibited the use of Red No. 3 in cosmetics after studies found tumors linked to the dye in lab rats ...

27,587 people played the daily Crossword recently. Can you solve it faster than others?27,587 people played the daily Crossword recently. Can you solve it faster than others? Suits ' Gabriel Macht ...

Next to artificial intelligence, weight-loss drugs ... so in pill form. While Wegovy and Zepbound are injectables, both pharma giants are also pursuing pill formulations. Eli Lilly has a deep ...

Lilly plans to share its full Q4 2024 results on 6 February 2025. Credit: JHVEPhoto via Getty Images. Eli Lilly has announced a $400m reduction in its 2024 revenue forecast, marking a 3% shortfall ...

smaller rivals for share of the exploding weight loss and diabetes drug market. Eli Lilly is developing an obesity pill that would be more convenient for patients and easier to manufacture ...